Other languages Rakovina Therapeutics Inc.

Equities

RKV

CA75103L1013

Market Closed - Toronto S.E. Other stock markets 15:54:38 26/04/2024 BST			5-day change	1st Jan Change
0.09 ^CAD	0.00%		0.00%	+5.88%

04-09	Rakovina Therapeutics Presents At American Association Of Cancer Research Annual Meeting	MT
2023	Rakovina Therapeutics Announces Appointment to Scientific Advisory Board	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rakovina Therapeutics Presents At American Association Of Cancer Research Annual Meeting	04-09
Rakovina Therapeutics Announces Appointment to Scientific Advisory Board	11-27
Rakovina Therapeutics Appoints Prof. Artem Cherkasov to the Scientific Advisory Board	11-27
Rakovina Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-26
Rakovina Therapeutics Inc. Announces Appointment of Prof. Petra Hamerlik as New Scientific Advisory Board Member	11-20
Rakovina Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/08/23
Rakovina Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	29/05/23
Rakovina Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/04/23
Rakovina Therapeutics Inc. Announces Presentation of New KT-3000 Series Data At AACR Annual Meeting	20/04/23
Rakovina Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/11/22
Rakovina Therapeutics Second-Quarter Loss Narrows on Lower Spending	11/08/22
Rakovina Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/08/22
Rakovina Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	24/05/22
Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas	11/05/22
Rakovina Therapeutics Reports Q4 Net Loss of $751K	27/04/22
Rakovina Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	25/04/22
Rakovina Therapeutics Presents Preclinical Data For kt-4000 Series Compounds at AACR Annual Meeting	12/04/22
Rakovina Therapeutics Presents Evaluation of A Novel Class of Bifunctional DNA Alkylating PARP Inhibitors	12/04/22
Rakovina Therapeutics : Receives Notice of Allowance for New U.S. Patent	07/10/21
Rakovina Therapeutics Inc. Reports Earnings Results for the Second Quarter Ending June 30, 2021	26/08/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Rakovina Therapeutics Inc.

Equities

RKV

CA75103L1013

Other languages

Filters